Anne S. Tsao, MD of MD Anderson Cancer Center discusses mesothelioma trends in 2018 with PrECOG and Ipi Nivo v chemo. For mesothelioma, the most interesting area is on the front-line chemotherapy and immunotherapy combinations. In the United States, theres the PrECOG Trial and the Bristol-Myers Squibb and its response to trial of Ipi Nivo versus chemo. These are more interesting to see as they are all randomized trials and it's challenging as there is a need for huge number of patients. However, in 2018, a preliminary readout will be made for these. So, stay updated!